Chugai Pharma Focuses On Licensing Antibody Mass-Production Methods
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical has embarked on a global effort to license its antibody drug mass-production technology, with a focus on Europe and the U.S.